Article successfully added.

CyFlow™ CD26 Purified

CyFlow™ CD26 Purified
Alternative Name: ADABP , ADCP2, CD26, DPPIV, TP103
Antibody: Yes
Antigen: CD26
Application: Flow cytometry
Clonality: monoclonal
Clone: BA5b
Field of Interest: Immunophenotyping
Format/Fluorochrome: Purified
Isotype: IgG2a
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CG749747

For Research Use Only

Build Your Own Reagent Panel
HLDA Workshop HLDA VI—WS Code N-L078 Concentration Unit mg/mL Concentration 1... more
CyFlow™ CD26 Purified
HLDA WorkshopHLDA VI—WS Code N-L078
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenA human T cell clone
Background InformationCD26 (DPP-IV; dipeptidyl peptidase IV) is a homodimeric cell surface serine peptidase that degradates IFN-γ-induced cytokines, acts as a T cell costimulatory molecule, and participates in multiple immunopathological roles in leukocyte homing and inflammation. Alterations in its peptidase activity are characteristic of malignant transformation. The enzymatic activity increases dramatically with tumor grade and severity. CD26 is expressed in various blood cell types, but also e.g. in cells that are histogenetically related to activated fibroblasts. Alterations in CD26 density have been reported on circulating monocytes and CD4+ T cells during rheumatoid arthritis and systemic lupus erythematosus.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K: In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol. 2007 Oct; 66(4):451‑7. < PMID: 17850590 > | Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C, Sedo A: Expression and enzymatic activity of dipeptidyl peptidase‑IV in human astrocytic tumours are associated with tumour grade. Int J Oncol. 2007 Oct; 31(4):785‑92. < PMID: 17786309 > | Kotacková L, Baláziová E, Sedo A: Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia Biol (Praha). 2009; 55(3):77‑84. < PMID: 19545486 > | Wong PT, Wong CK, Tam LS, Li EK, Chen DP, Lam CW: Decreased expression of T lymphocyte co‑stimulatory molecule CD26 on invariat natural killer T cells in systemic lupus erythematosus. Immunol Invest. 2009; 38(5):350‑64. < PMID: 19811413 > | Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, Kokubun S: Histogenesis‑specific expression of fibroblast activation proteinand dipeptidylpeptidase‑IV in human bone and soft tissue tumours. Histopathology. 2009 Oct; 55(4):432‑40. < PMID: 19817894 >